Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

Moderna’s guidance for fiscal year 2025 (FY2%) revenue from the respiratory vaccine business is between $1.5 billion and $2.5 billion, aligning with Goldman’s estimate of $1.5 billion.

Goldman Sachs updated its Sharpe Ratio basket, a list of 50 stocks with the highest expected risk-adjusted returns in the ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BIT:1MRNA) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting positions in Moderna ...

As per Goldman, this bifurcation implies that the equal-weight flagship S&P index is likely to outperform the market cap-weighted index “by an annualized 200 bp-800 bp” over the next decade ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance repre ...

Goldman Sachs remarks that Moderna expects to break even at ~$6 billion in revenue and achieve that in 2028 on a cash-cost basis.. Analyst Reaction: Piper Sandler reiterates Moderna with an ...

The Goldman team also says Moderna won't be cash break-even until 2029, citing elevated operating expenses. Moderna is targeting that accomplishment by 2028, having delayed it from its previous ...

Goldman Sachs just updated one of its stock baskets with its picks for the highest risk-adjusted returns. The basket has outperformed the S&P 500 so far this year, gaining 3% year-to-date. The S&P ...

Moderna (NASDAQ: MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.. The downgrade follows a series of negative revisions to ...